FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977885350> ?p ?o ?g. }

• W2977885350 endingPage "v785" @default.
• W2977885350 startingPage "v785" @default.
• W2977885350 abstract "Abstract Background PI3K/AKT/mTOR and MEK/ERK signalling pathways act cooperatively to develop taxane resistance in metastatic castration resistant prostate cancer (mCRPC). Inhibition of one of the pathways promotes a negative feedback that activates the other one. Co-inhibition of both pathways increases anti-tumor efficacy in preclinical models of PC. Our aim was to demonstrate whether combinations of Selumetinib (SELU; MEK inhibitor) + Capivasertib (CAPI; AKT inhibitor) or AZD8186 (PI3Kβ/δ inhibitor) could potentiate the effect of Cabazitaxel (CABA) treatment and revert resistance to Docetaxel (DOCE) in in vitro models. Methods The effect of drug treatments on the proliferation of DOCE-acquired resistant cells DU145-DR (PTEN WT/K-RAS MUT) and PC3-DR (PTEN Null/K-RAS WT) was determined by MTT assay and the median effect lines method; synergism was calculated using CompuSyn software. Phosphorylation status of AKT, ERK, GSK3β, S6 and p90RSK was analysed by Western Blot at basal level and after treatments. Results As compared to parental cells, p-AKT was significantly increased in DU145-DR and PC3-DR cells while p-ERK was increased in DU145-DR and decreased in PC3-DR. AZD8186 and CAPI alone showed little effect on DU145-DR cell viability (IC50>50µM). In contrast, both drugs decreased PC3-DR cell viability with IC50s of 0.5 and 1.5µM, respectively. SELU had no effect on proliferation of any cell line. SELU + CAPI and SELU + AZD8186 72h-concomitant treatment decreased DU145-DR proliferation in a highly synergistic manner, particularly the SELU + AZD8186 combination. Accordingly, this treatment was the more efficient in decreasing p-AKT and p-ERK. However, the addition of SELU didn’t enhance the efficacy of CAPI or AZD8186 in PC3-DR cells. SELU + AZD8186 promoted a dramatic increase of CABA and DOCE cytotoxicity in DU145-DR cells. Conclusions These results suggest that the combination of SELU + AZD8186 is highly synergistic at least in DU145-DR cells, leading to a very strong CABA sensitization and DOCE resistance reversion through the inhibition of AKT and ERK activation. Further experiments are ongoing in order to elucidate the role of these drugs in taxane sensitivity of PC3-DR and CABA-acquired resistant cells. Legal entity responsible for the study The authors. Funding AstraZeneca. Disclosure All authors have declared no conflicts of interest." @default.
• W2977885350 created "2019-10-10" @default.
• W2977885350 creator A5008678006 @default.
• W2977885350 creator A5010040304 @default.
• W2977885350 creator A5017537885 @default.
• W2977885350 creator A5024309839 @default.
• W2977885350 creator A5026787156 @default.
• W2977885350 creator A5027322202 @default.
• W2977885350 creator A5032860719 @default.
• W2977885350 creator A5085349056 @default.
• W2977885350 date "2019-10-01" @default.
• W2977885350 modified "2023-10-07" @default.
• W2977885350 title "Effect of selumetinib plus AZD8186 treatment on cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines" @default.
• W2977885350 doi "https://doi.org/10.1093/annonc/mdz268.077" @default.
• W2977885350 hasPublicationYear "2019" @default.
• W2977885350 type Work @default.
• W2977885350 sameAs 2977885350 @default.
• W2977885350 citedByCount "1" @default.
• W2977885350 countsByYear W29778853502020 @default.
• W2977885350 crossrefType "journal-article" @default.
• W2977885350 hasAuthorship W2977885350A5008678006 @default.
• W2977885350 hasAuthorship W2977885350A5010040304 @default.
• W2977885350 hasAuthorship W2977885350A5017537885 @default.
• W2977885350 hasAuthorship W2977885350A5024309839 @default.
• W2977885350 hasAuthorship W2977885350A5026787156 @default.
• W2977885350 hasAuthorship W2977885350A5027322202 @default.
• W2977885350 hasAuthorship W2977885350A5032860719 @default.
• W2977885350 hasAuthorship W2977885350A5085349056 @default.
• W2977885350 hasBestOaLocation W29778853501 @default.
• W2977885350 hasConcept C121608353 @default.
• W2977885350 hasConcept C126322002 @default.
• W2977885350 hasConcept C143998085 @default.
• W2977885350 hasConcept C2776087337 @default.
• W2977885350 hasConcept C2776694085 @default.
• W2977885350 hasConcept C2777899217 @default.
• W2977885350 hasConcept C2778971682 @default.
• W2977885350 hasConcept C2780192828 @default.
• W2977885350 hasConcept C2781187634 @default.
• W2977885350 hasConcept C2781190966 @default.
• W2977885350 hasConcept C502942594 @default.
• W2977885350 hasConcept C526805850 @default.
• W2977885350 hasConcept C71924100 @default.
• W2977885350 hasConceptScore W2977885350C121608353 @default.
• W2977885350 hasConceptScore W2977885350C126322002 @default.
• W2977885350 hasConceptScore W2977885350C143998085 @default.
• W2977885350 hasConceptScore W2977885350C2776087337 @default.
• W2977885350 hasConceptScore W2977885350C2776694085 @default.
• W2977885350 hasConceptScore W2977885350C2777899217 @default.
• W2977885350 hasConceptScore W2977885350C2778971682 @default.
• W2977885350 hasConceptScore W2977885350C2780192828 @default.
• W2977885350 hasConceptScore W2977885350C2781187634 @default.
• W2977885350 hasConceptScore W2977885350C2781190966 @default.
• W2977885350 hasConceptScore W2977885350C502942594 @default.
• W2977885350 hasConceptScore W2977885350C526805850 @default.
• W2977885350 hasConceptScore W2977885350C71924100 @default.
• W2977885350 hasLocation W29778853501 @default.
• W2977885350 hasOpenAccess W2977885350 @default.
• W2977885350 hasPrimaryLocation W29778853501 @default.
• W2977885350 hasRelatedWork W122177069 @default.
• W2977885350 hasRelatedWork W1543388821 @default.
• W2977885350 hasRelatedWork W2094570582 @default.
• W2977885350 hasRelatedWork W2135620818 @default.
• W2977885350 hasRelatedWork W2299690226 @default.
• W2977885350 hasRelatedWork W2568045406 @default.
• W2977885350 hasRelatedWork W2588988563 @default.
• W2977885350 hasRelatedWork W2735900144 @default.
• W2977885350 hasRelatedWork W2776356588 @default.
• W2977885350 hasRelatedWork W3132581442 @default.
• W2977885350 hasVolume "30" @default.
• W2977885350 isParatext "false" @default.
• W2977885350 isRetracted "false" @default.
• W2977885350 magId "2977885350" @default.
• W2977885350 workType "article" @default.